Bolt Biotherapeutics (NASDAQ:BOLT) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Bolt Biotherapeutics (NASDAQ:BOLT) announced its quarterly earnings results on Tuesday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04), Zacks reports. The business had revenue of $1.14 million during the quarter, compared to analyst estimates of $1.02 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 64.49%.

Bolt Biotherapeutics Stock Performance

BOLT traded up $0.01 on Thursday, hitting $0.63. 9,869 shares of the company traded hands, compared to its average volume of 164,873. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 0.19. The company has a 50 day moving average of $0.64 and a 200-day moving average of $0.74. Bolt Biotherapeutics has a 12-month low of $0.55 and a 12-month high of $1.56. The stock has a market capitalization of $23.95 million, a PE ratio of -0.36 and a beta of 0.92.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Wednesday. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Bolt Biotherapeutics currently has an average rating of “Hold” and a consensus target price of $3.50.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.